title: Assessment of radioiodine clearance in patients with differentiated thyroid cancer.
abstract: Radioiodine ((131)I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria for the release from medical confinement of patients who receive such radionuclide therapy. Over a 6-y period, the external whole-body dose rates at 1 m from 562 DTC patients were measured with an ionisation chamber calibrated in microsieverts per hour out to 5-d post-administration. Patients were stratified into four administered activity groups: 3.7 GBq (36.8 %), 5.55 GBq (47.3 %), 7.4 GBq (12.8 %) and 9.25 GBq (3 %). Consistent with previously published data, the current study demonstrated that a bi-phasic model accurately described (131)I-iodide kinetics up to at least 5-d post-administration in DTC patients, providing data that would be useful in formulating radiation safety guidelines for staff and other individuals coming into contact with such patients after treatment.
authors.affiliation: Department of Medical Physics and Engineering,  Shahid Beheshti University of Medical Sciences, Tehran,  Iran.
authors.forename: Faraj
authors.initials: F
authors.lastname: Tabei
authors.forename: Isa
authors.initials: I
authors.lastname: Neshandar Asli
authors.forename: Zahra
authors.initials: Z
authors.lastname: Azizmohammadi
authors.forename: Hamid
authors.initials: H
authors.lastname: Javadi
authors.forename: Majid
authors.initials: M
authors.lastname: Assadi
mesh_terms: D000328:Adult; D001681:Biological Assay / Q000379:methods; D001822:Body Burden; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D011829:Radiation Dosage; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D014915:Whole-Body Counting / Q000379:methods*
chemical_list: D007457:Iodine Radioisotopes